Delving into the Latest Updates on HIV vaccine(Haikou Vti Biological Institute) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

HIV vaccine

+ [1]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication

Acquired Immunodeficiency Syndrome

Originator Organization

Haikou VTI Biological Institute

Active Organization

Haikou VTI Biological Institute

Inactive Organization

Guangdong South China New Drug Creation Center

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

[Translation] Exploring the efficacy and safety of the therapeutic (recombinant core antigen) AIDS vaccine B.C (LFnp24B.C) in combination with ART for the treatment of HIV-1 infected patients Multi-center Phase II clinical trial: LFnp24B.C Exploratory study of "functional cure" for HIV-1 infected patients in China

主要研究目的：评价 LFnp24B.C 联合 ART 治疗在抗病毒治疗中断（ATI）后对 HIV-1 感染者病毒载量的影响。次要研究目的： 1）评价 LFnp24B.C 联合 ART 治疗在 HIV-1 感染者中的安全性和免疫原性； 2）评价 LFnp24B.C 联合 ART 治疗对 HIV-1 感染者病毒储存库的影响。

[Translation]

Primary study objectives: To evaluate the effect of LFnp24B.C combined with ART treatment on the viral load of HIV-1 infected individuals after antiviral treatment interruption (ATI). Secondary study objectives: 1) To evaluate the safety and immunogenicity of LFnp24B.C combined with ART treatment in HIV-1 infected individuals; 2) To evaluate the effect of LFnp24B.C combined with ART treatment on the viral reservoir of HIV-1 infected individuals.

Start Date-

Sponsor / Collaborator

Haikou VTI Biological Institute

CTR20130371

/ CompletedPhase 1

随机、双盲、安慰剂对照评价治疗用（重组核心抗原）艾滋病疫苗B.C安全性和免疫原性I期临床试验

[Translation] A randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of the therapeutic (recombinant core antigen) AIDS vaccine B.C.

1.主要研究目的：评价LFn-p24B.C在ART治疗稳定的HIV-1 感染的HIV/AIDS患者中的安全性和耐受性 2.次要研究目的：评价LFn-p24B.C在ART治疗稳定的HIV-1 感染的HIV/AIDS患者中诱导特异性T细胞应答的能力

[Translation]

1. Primary study objective: To evaluate the safety and tolerability of LFn-p24B.C in HIV/AIDS patients with stable HIV-1 infection on ART 2. Secondary study objective: To evaluate the ability of LFn-p24B.C to induce specific T cell responses in HIV/AIDS patients with stable HIV-1 infection on ART

Start Date21 Apr 2014

Sponsor / Collaborator

Guangdong South China New Drug Creation Center

[+1]

ChiCTR-TRC-14004485

/ CompletedPhase 1IIT

A Randomized, Double-blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of LFnp24B.C, a Therapeutic HIV Vaccine,in HIV-infected Chinese Patients Receiving Stable ART treatment

Start Date10 Apr 2014

Sponsor / Collaborator-

100 Clinical Results associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

100 Translational Medicine associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

100 Patents (Medical) associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

239

Literatures (Medical) associated with HIV vaccine(Haikou Vti Biological Institute)

01 Jul 2025·Microbial Pathogenesis

Harnessing nanotechnology in HIV therapy: Exploring molecular pathogenesis and treatment strategies with special reference to chemotherapy and immunotherapy

Review

Author: Dev, Abhimanyu ; Ash, Kaushiki

Human immunodeficiency virus (HIV) continues to be a global threat, contributing substantially to social and economic burdens worldwide. Synthetic ARV drugs are classified into six different classes viz NRTIs, NNRTIs, PIs, IIs, INSTIs, and FIs. Highly active anti-retroviral therapy (HAART) which is a combination of two or more ARV drugs from different classes is gaining immense popularity in the HIV therapy regimen due to its better therapeutic outcome. However, despite its successful endeavor in significant viral suppression, synthetic drugs are associated with numerous adverse effects. To mitigate this issue, scientists are exploring ARV agents derived from various natural sources like plants, and marine organisms that can exhibit potent anti-HIV activity with minimal side effects. Nevertheless, both synthetically and naturally derived ARV agents have failed to exhibit eradication of HIV from latent reservoirs. Henceforth, researchers are shifting their attention towards formulating a drug-encapsulated nano-delivery system to ensure a significant amount of drug delivery into these reservoirs. Additionally, the discovery of a novel HIV vaccine that can induce robust immune responses against multiple HIV strains and facilitate complete removal of the virus before the establishment of a latent reservoir is the need of an hour. Briefly, we discussed various synthetic and natural chemotherapeutic agents along with their specificity and limitations, different drug-delivery devices for ART, immunotherapy, vaccines, and lastly, challenges and strategies associated with vaccine development.

24 Apr 2025·New England Journal of Medicine

An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant?

Article

Author: Kublin, James G. ; Gray, Glenda E. ; Mgodi, Nyaradzo M. ; Buchbinder, Susan P. ; Jatt, Lauren P.

08 Jan 2025·Science Translational Medicine

An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations

Article

Author: Bar, Maggie ; Jiang, Chuancang ; Parks, Rob ; Rhodes, Brianna ; Newman, Amanda ; Saunders, Kevin O. ; Cronin, Kenneth ; Frazier, McKenzie ; Cheng, Hwei-Ling ; Davis, Jillian ; Swanson, Olivia M. ; Van Itallie, Elizabeth ; Brown, Alecia R. ; Edwards, Robert J. ; Harris, Caitlin ; Azoitei, Mihai L. ; Alt, Fred ; Tian, Ming ; Venkatayogi, Sravani ; Cain, Derek ; Acharya, Priyamvada ; Wiehe, Kevin ; Haynes, Barton F. ; Alam, S. Munir ; Kapingidza, Anyway Brenda ; Smith, Lena M. ; Martin Beem, Joshua S. ; Zhang, Qianyi E. ; McGovern, Kelly

Elicitation of HIV broadly neutralizing antibodies (bnAbs) by vaccination first requires the activation of diverse precursors, followed by successive boosts that guide these responses to enhanced breadth through the acquisition of somatic mutations. Because HIV bnAbs contain mutations in their B cell receptors (BCRs) that are rarely generated during conventional B cell maturation, HIV vaccine immunogens must robustly engage and expand B cells with BCRs that contain these improbable mutations. Here, we engineered an immunogen that activates diverse precursors of an HIV V3-glycan bnAb and promotes their acquisition of a functionally critical improbable mutation. This immunogen was validated biochemically, structurally, and in three different humanized immunoglobulin mouse models that were designed to test HIV immunogens. These results provide a blueprint for rationally designing priming immunogens that explicitly target the elicitation of antibodies with functional yet improbable mutations.

100 Deals associated with HIV vaccine(Haikou Vti Biological Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	China	Haikou VTI Biological Institute	12 Jan 2021
Acquired Immunodeficiency Syndrome	Phase 2	China	Haikou VTI Biological Institute	21 Apr 2014
Acquired Immunodeficiency Syndrome	Phase 2	China	Guangdong South China New Drug Creation Center	21 Apr 2014